TIDMAREC
RNS Number : 6906G
Arecor Therapeutics PLC
17 November 2022
Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
Grant of AESOP Options, PDMR Dealing
Cambridge, UK, 17 November 2022: Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical group advancing today's therapies to
enable healthier lives , announces that on 16 November 2022, it
granted a total of 323,500 options under the Company's All Employee
Share Ownership Plan ("AESOP Options") over new ordinary shares of
0.1 pence each in the Company ("Ordinary Shares").
The AESOP Options vest after 36 months and are exercisable at
GBP2.45 per share being the closing market price of an Ordinary
Share on the day preceding the date of grant. The AESOP Options are
subject to continuous employment, vest in accordance with the
vesting term notified to the option holder and are exercisable
until the tenth anniversary of the date of grant, after which date
the option will lapse.
The following 159,000 AESOP Options were granted to persons
discharging managerial responsibilities ("PDMR"):
PDMR Position/status Number of AESOP Total number
options granted of AESOP options
on 16 November held
2022
Managing Director,
Shafiq Choudhary Tetris Pharma 40,000 40,000
------------------------- ----------------- ------------------
David Gerring VP Development 40,000 70,000
------------------------- ----------------- ------------------
Chief Executive
Sarah Howell Officer 33,000 133,000
------------------------- ----------------- ------------------
Chief Scientific
Jan Jezek Officer 13,000 53,000
------------------------- ----------------- ------------------
VP Clinical Development
Fiona Lawrence and Reg. Affairs 10,000 40,000
------------------------- ----------------- ------------------
Chief Financial
Susan Lowther Officer 23,000 93,000
------------------------- ----------------- ------------------
The notifications below, made in accordance with the
requirements of the Market Abuse Regulation, provide further
detail.
For further information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Tel: +44 (0) 1223 426060
Officer Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited Tel: +44 (0) 20 7886 2500
(NOMAD and Broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Tel: +44 (0) 20 3709 5700
Gray Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
company transforming patient care by bringing innovative medicines
to market through the enhancement of existing therapeutic products.
By applying our innovative proprietary formulation technology
platform, Arestat(TM), we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat (TM) platform is supported by an extensive patent
portfolio.
For further details please see our website, www.arecor.com
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
Details of the person discharging managerial responsibilities/person
closely associated
a) Name: Shafiq Choudhary
---------------------------------- -----------------------------------
2. Reason for the notification
-----------------------------------------------------------------------
a) Position/status: Managing Director, Tetris
Pharma
---------------------------------- -----------------------------------
b) Initial notification/Amendment: Initial notification
---------------------------------- -----------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name: Arecor Therapeutics plc
---------------------------------- -----------------------------------
b) LEI: 98450093D12I3A8DDD58
---------------------------------- -----------------------------------
4. Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
-----------------------------------------------------------------------
a) Description of the financial Ordinary shares of 1 pence
instrument, type of instrument: each
Identification code: GB00BMWLM973
---------------------------------- -----------------------------------
b) Nature of the transaction: Grant of options over ordinary
shares
---------------------------------- -----------------------------------
c) Price(s) and volume(s): Exercise Price(s) Volume(s)
GBP2.45 40,000
----------
---------------------------------- -----------------------------------
d) Aggregated information:
* Aggregated volume: 40,000
N/A
* Price:
---------------------------------- -----------------------------------
e) Date of the transaction: 16 November 2022
---------------------------------- -----------------------------------
f) Place of the transaction: Outside of a trading venue
---------------------------------- -----------------------------------
Details of the person discharging managerial responsibilities/person
closely associated
a) Name: David Gerring
---------------------------------- -----------------------------------
2. Reason for the notification
-----------------------------------------------------------------------
a) Position/status: VP Development
---------------------------------- -----------------------------------
b) Initial notification/Amendment: Initial notification
---------------------------------- -----------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name: Arecor Therapeutics plc
---------------------------------- -----------------------------------
b) LEI: 98450093D12I3A8DDD58
---------------------------------- -----------------------------------
4. Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
-----------------------------------------------------------------------
a) Description of the financial Ordinary shares of 1 pence each
instrument, type of instrument: GB00BMWLM973
Identification code:
---------------------------------- -----------------------------------
b) Nature of the transaction: Grant of options over ordinary
shares
---------------------------------- -----------------------------------
c) Price(s) and volume(s): Exercise Price(s) Volume(s)
GBP2.45 40,000
----------
---------------------------------- -----------------------------------
d) Aggregated information:
* Aggregated volume: 40,000
N/A
* Price:
---------------------------------- -----------------------------------
e) Date of the transaction: 16 November 2022
---------------------------------- -----------------------------------
f) Place of the transaction: Outside of a trading venue
---------------------------------- -----------------------------------
Details of the person discharging managerial responsibilities/person
closely associated
a) Name: Sarah Howell
---------------------------------- -----------------------------------
2. Reason for the notification
-----------------------------------------------------------------------
a) Position/status: Chief Executive Officer
---------------------------------- -----------------------------------
b) Initial notification/Amendment: Initial notification
---------------------------------- -----------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name: Arecor Therapeutics plc
---------------------------------- -----------------------------------
b) LEI: 98450093D12I3A8DDD58
---------------------------------- -----------------------------------
4. Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
-----------------------------------------------------------------------
a) Description of the financial Ordinary shares of 1 pence each
instrument, type of instrument: GB00BMWLM973
Identification code:
---------------------------------- -----------------------------------
b) Nature of the transaction: Grant of options over ordinary
shares
---------------------------------- -----------------------------------
c) Price(s) and volume(s): Exercise Price(s) Volume(s)
GBP2.45 33,000
----------
---------------------------------- -----------------------------------
d) Aggregated information:
* Aggregated volume: 33,000
N/A
* Price:
---------------------------------- -----------------------------------
e) Date of the transaction: 16 November 2022
---------------------------------- -----------------------------------
f) Place of the transaction: Outside of a trading venue
---------------------------------- -----------------------------------
Details of the person discharging managerial responsibilities/person
closely associated
a) Name: Jan Jezek
---------------------------------- -----------------------------------
2. Reason for the notification
-----------------------------------------------------------------------
a) Position/status: Chief Scientific Officer
---------------------------------- -----------------------------------
b) Initial notification/Amendment: Initial notification
---------------------------------- -----------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name: Arecor Therapeutics plc
---------------------------------- -----------------------------------
b) LEI: 98450093D12I3A8DDD58
---------------------------------- -----------------------------------
4. Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
-----------------------------------------------------------------------
a) Description of the financial Ordinary shares of 1 pence each
instrument, type of instrument: GB00BMWLM973
Identification code:
---------------------------------- -----------------------------------
b) Nature of the transaction: Grant of options over ordinary
shares
---------------------------------- -----------------------------------
c) Price(s) and volume(s): Exercise Price(s) Volume(s)
GBP2.45 13,000
----------
---------------------------------- -----------------------------------
d) Aggregated information:
* Aggregated volume: 13,000
N/A
* Price:
---------------------------------- -----------------------------------
e) Date of the transaction: 16 November 2022
---------------------------------- -----------------------------------
f) Place of the transaction: Outside of a trading venue
---------------------------------- -----------------------------------
Details of the person discharging managerial responsibilities/person
closely associated
a) Name: Fiona Lawrence
---------------------------------- -----------------------------------
2. Reason for the notification
-----------------------------------------------------------------------
a) Position/status: VP Clinical Development and
Reg. Affairs
---------------------------------- -----------------------------------
b) Initial notification/Amendment: Initial notification
---------------------------------- -----------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name: Arecor Therapeutics plc
---------------------------------- -----------------------------------
b) LEI: 98450093D12I3A8DDD58
---------------------------------- -----------------------------------
4. Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
-----------------------------------------------------------------------
a) Description of the financial Ordinary shares of 1 pence each
instrument, type of instrument: GB00BMWLM973
Identification code:
---------------------------------- -----------------------------------
b) Nature of the transaction: Grant of options over ordinary
shares
---------------------------------- -----------------------------------
c) Price(s) and volume(s): Exercise Price(s) Volume(s)
GBP2.45 10,000
----------
---------------------------------- -----------------------------------
d) Aggregated information:
* Aggregated volume: 10,000
N/A
* Price:
---------------------------------- -----------------------------------
e) Date of the transaction: 16 November 2022
---------------------------------- -----------------------------------
f) Place of the transaction: Outside of a trading venue
---------------------------------- -----------------------------------
Details of the person discharging managerial responsibilities/person
closely associated
a) Name: Susan Lowther
---------------------------------- -----------------------------------
2. Reason for the notification
-----------------------------------------------------------------------
a) Position/status: Chief Financial Officer
---------------------------------- -----------------------------------
b) Initial notification/Amendment: Initial notification
---------------------------------- -----------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name: Arecor Therapeutics plc
---------------------------------- -----------------------------------
b) LEI: 98450093D12I3A8DDD58
---------------------------------- -----------------------------------
4. Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
-----------------------------------------------------------------------
a) Description of the financial Ordinary shares of 1 pence each
instrument, type of instrument: GB00BMWLM973
Identification code:
---------------------------------- -----------------------------------
b) Nature of the transaction: Grant of options over ordinary
shares
---------------------------------- -----------------------------------
c) Price(s) and volume(s): Exercise Price(s) Volume(s)
GBP2.45 23,000
----------
---------------------------------- -----------------------------------
d) Aggregated information:
* Aggregated volume: 23,000
N/A
* Price:
---------------------------------- -----------------------------------
e) Date of the transaction: 16 November 2022
---------------------------------- -----------------------------------
f) Place of the transaction: Outside of a trading venue
---------------------------------- -----------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEANFKFDKAFFA
(END) Dow Jones Newswires
November 17, 2022 02:00 ET (07:00 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jul 2023 to Jul 2024
